New Delhi (ANTARA News/Asia Pulse) - Ranbaxy Laboratories (BSE:500359) has recalled from the US market a batch of 4,348 cartons of Sotret Isotretinoin capsules used in treating skin infections.

According to information from the US health regulator Food and Drug Administration (FDA) website, Ranbaxy through its US-based subsidiary Ranbaxy Laboratories Inc, has issued a 'nation-wide class III recall' for a batch of Sotret Isotretinoin capsules of 40 mg strength.

The company has issued the recall after ceratin reports suggested that the product may "exceed impurity specifications" during its shelf life period. However, a class III recall signifies that the use of the product is not likely to be harmful.
 

Source:
Business in Asia Today - Nov 23, 2009
published by <a href="http://www.asiapulse.com">Asia Pulse</a>

Editor:
COPYRIGHT © 2012

Comment
Send Comment